|
Gene: CEBPB |
Gene summary for CEBPB |
Gene summary. |
Gene information | Species | Human | Gene symbol | CEBPB | Gene ID | 1051 |
Gene name | CCAAT enhancer binding protein beta | |
Gene Alias | C/EBP-beta | |
Cytomap | 20q13.13 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P17676 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1051 | CEBPB | GSM4909281 | Human | Breast | IDC | 1.13e-13 | -4.70e-01 | 0.21 |
1051 | CEBPB | GSM4909282 | Human | Breast | IDC | 9.04e-09 | 3.99e-01 | -0.0288 |
1051 | CEBPB | GSM4909285 | Human | Breast | IDC | 2.47e-14 | -4.14e-01 | 0.21 |
1051 | CEBPB | GSM4909286 | Human | Breast | IDC | 1.52e-14 | -3.37e-01 | 0.1081 |
1051 | CEBPB | GSM4909287 | Human | Breast | IDC | 5.16e-05 | -3.39e-01 | 0.2057 |
1051 | CEBPB | GSM4909290 | Human | Breast | IDC | 2.81e-08 | -3.94e-01 | 0.2096 |
1051 | CEBPB | GSM4909291 | Human | Breast | IDC | 3.22e-05 | -4.26e-01 | 0.1753 |
1051 | CEBPB | GSM4909293 | Human | Breast | IDC | 7.02e-07 | -3.30e-01 | 0.1581 |
1051 | CEBPB | GSM4909294 | Human | Breast | IDC | 1.96e-19 | -6.53e-01 | 0.2022 |
1051 | CEBPB | GSM4909296 | Human | Breast | IDC | 5.83e-35 | -8.41e-01 | 0.1524 |
1051 | CEBPB | GSM4909297 | Human | Breast | IDC | 7.11e-35 | -8.18e-01 | 0.1517 |
1051 | CEBPB | GSM4909298 | Human | Breast | IDC | 6.91e-08 | -9.70e-02 | 0.1551 |
1051 | CEBPB | GSM4909301 | Human | Breast | IDC | 1.44e-15 | -5.79e-01 | 0.1577 |
1051 | CEBPB | GSM4909302 | Human | Breast | IDC | 3.72e-23 | -6.96e-01 | 0.1545 |
1051 | CEBPB | GSM4909304 | Human | Breast | IDC | 4.15e-05 | -3.02e-01 | 0.1636 |
1051 | CEBPB | GSM4909305 | Human | Breast | IDC | 5.32e-12 | -4.98e-01 | 0.0436 |
1051 | CEBPB | GSM4909306 | Human | Breast | IDC | 2.53e-23 | -6.58e-01 | 0.1564 |
1051 | CEBPB | GSM4909307 | Human | Breast | IDC | 3.32e-32 | -8.10e-01 | 0.1569 |
1051 | CEBPB | GSM4909308 | Human | Breast | IDC | 6.12e-20 | -6.04e-01 | 0.158 |
1051 | CEBPB | GSM4909309 | Human | Breast | IDC | 1.77e-06 | -3.95e-01 | 0.0483 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00308798 | Endometrium | AEH | mammary gland development | 26/2100 | 137/18723 | 4.97e-03 | 3.13e-02 | 26 |
GO:0070167 | Endometrium | AEH | regulation of biomineral tissue development | 20/2100 | 97/18723 | 5.00e-03 | 3.14e-02 | 20 |
GO:00071627 | Endometrium | AEH | negative regulation of cell adhesion | 49/2100 | 303/18723 | 5.43e-03 | 3.37e-02 | 49 |
GO:00706638 | Endometrium | AEH | regulation of leukocyte proliferation | 41/2100 | 245/18723 | 5.77e-03 | 3.52e-02 | 41 |
GO:190121416 | Endometrium | AEH | regulation of neuron death | 51/2100 | 319/18723 | 5.82e-03 | 3.55e-02 | 51 |
GO:00335985 | Endometrium | AEH | mammary gland epithelial cell proliferation | 8/2100 | 26/18723 | 6.03e-03 | 3.63e-02 | 8 |
GO:00455981 | Endometrium | AEH | regulation of fat cell differentiation | 26/2100 | 139/18723 | 6.04e-03 | 3.64e-02 | 26 |
GO:0110149 | Endometrium | AEH | regulation of biomineralization | 20/2100 | 99/18723 | 6.34e-03 | 3.76e-02 | 20 |
GO:0070169 | Endometrium | AEH | positive regulation of biomineral tissue development | 12/2100 | 49/18723 | 6.75e-03 | 3.94e-02 | 12 |
GO:00712293 | Endometrium | AEH | cellular response to acid chemical | 17/2100 | 80/18723 | 6.76e-03 | 3.94e-02 | 17 |
GO:00312141 | Endometrium | AEH | biomineral tissue development | 30/2100 | 169/18723 | 7.31e-03 | 4.18e-02 | 30 |
GO:007099716 | Endometrium | AEH | neuron death | 56/2100 | 361/18723 | 7.51e-03 | 4.26e-02 | 56 |
GO:0110151 | Endometrium | AEH | positive regulation of biomineralization | 12/2100 | 50/18723 | 8.00e-03 | 4.43e-02 | 12 |
GO:00725744 | Endometrium | AEH | hepatocyte proliferation | 7/2100 | 22/18723 | 8.22e-03 | 4.51e-02 | 7 |
GO:00725754 | Endometrium | AEH | epithelial cell proliferation involved in liver morphogenesis | 7/2100 | 22/18723 | 8.22e-03 | 4.51e-02 | 7 |
GO:00712199 | Endometrium | AEH | cellular response to molecule of bacterial origin | 37/2100 | 221/18723 | 8.34e-03 | 4.56e-02 | 37 |
GO:01101481 | Endometrium | AEH | biomineralization | 30/2100 | 171/18723 | 8.63e-03 | 4.71e-02 | 30 |
GO:00705555 | Endometrium | AEH | response to interleukin-1 | 26/2100 | 143/18723 | 8.78e-03 | 4.78e-02 | 26 |
GO:009719317 | Endometrium | EEC | intrinsic apoptotic signaling pathway | 80/2168 | 288/18723 | 3.35e-14 | 9.13e-12 | 80 |
GO:003497617 | Endometrium | EEC | response to endoplasmic reticulum stress | 63/2168 | 256/18723 | 3.84e-09 | 2.71e-07 | 63 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0465716 | Breast | Precancer | IL-17 signaling pathway | 20/684 | 94/8465 | 4.74e-05 | 4.54e-04 | 3.48e-04 | 20 |
hsa0465717 | Breast | Precancer | IL-17 signaling pathway | 20/684 | 94/8465 | 4.74e-05 | 4.54e-04 | 3.48e-04 | 20 |
hsa0465721 | Breast | IDC | IL-17 signaling pathway | 18/867 | 94/8465 | 6.39e-03 | 3.30e-02 | 2.47e-02 | 18 |
hsa0465731 | Breast | IDC | IL-17 signaling pathway | 18/867 | 94/8465 | 6.39e-03 | 3.30e-02 | 2.47e-02 | 18 |
hsa05152 | Cervix | CC | Tuberculosis | 42/1267 | 180/8465 | 1.78e-03 | 7.21e-03 | 4.26e-03 | 42 |
hsa046686 | Cervix | CC | TNF signaling pathway | 28/1267 | 114/8465 | 4.60e-03 | 1.62e-02 | 9.59e-03 | 28 |
hsa051521 | Cervix | CC | Tuberculosis | 42/1267 | 180/8465 | 1.78e-03 | 7.21e-03 | 4.26e-03 | 42 |
hsa0466813 | Cervix | CC | TNF signaling pathway | 28/1267 | 114/8465 | 4.60e-03 | 1.62e-02 | 9.59e-03 | 28 |
hsa0465742 | Cervix | N_HPV | IL-17 signaling pathway | 16/349 | 94/8465 | 1.20e-06 | 1.64e-05 | 1.28e-05 | 16 |
hsa051524 | Cervix | N_HPV | Tuberculosis | 16/349 | 180/8465 | 3.05e-03 | 1.73e-02 | 1.35e-02 | 16 |
hsa0465752 | Cervix | N_HPV | IL-17 signaling pathway | 16/349 | 94/8465 | 1.20e-06 | 1.64e-05 | 1.28e-05 | 16 |
hsa051525 | Cervix | N_HPV | Tuberculosis | 16/349 | 180/8465 | 3.05e-03 | 1.73e-02 | 1.35e-02 | 16 |
hsa046687 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
hsa0466814 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
hsa0465726 | Esophagus | HGIN | IL-17 signaling pathway | 25/1383 | 94/8465 | 7.52e-03 | 4.63e-02 | 3.68e-02 | 25 |
hsa04657113 | Esophagus | HGIN | IL-17 signaling pathway | 25/1383 | 94/8465 | 7.52e-03 | 4.63e-02 | 3.68e-02 | 25 |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa0465727 | Esophagus | ESCC | IL-17 signaling pathway | 66/4205 | 94/8465 | 3.93e-05 | 1.75e-04 | 8.99e-05 | 66 |
hsa051527 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
CEBPB | ASC | Colorectum | MSS | RPS21,PMEPA1,SLC7A5, etc. | 4.19e-01 | |
CEBPB | STM | Oral cavity | Healthy | PTGES,MTHFD2L,TYMP, etc. | 4.29e-01 |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CEBPB | SNV | Missense_Mutation | novel | c.879N>T | p.Lys293Asn | p.K293N | P17676 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CEBPB | SNV | Missense_Mutation | novel | c.803A>G | p.Asp268Gly | p.D268G | P17676 | protein_coding | deleterious(0) | possibly_damaging(0.823) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |